Article
Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Clinical lung cancer - 1 Sept 2016
Zenke Yoshitaka, Yoh Kiyotaka, Matsumoto Shingo, Umemura Shigeki, Niho Seiji, Ohmatsu Hironobu, Goto Koichi, Ohe Yuichiro
Abstract excerpt
BACKGROUND: Gastric acid-suppressing medications (AS), namely, proton pump inhibitors and histamine-2 receptor antagonists, increase gastric pH, which may reduce the absorption of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors-erlotinib and gefitinib. PATIENTS AND METHODS: From 2008 to 2011, 130 consecutive patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.